| Laurel Health & Rehabilitation Center | |
|
820 3rd Ave, Laurel, MT 59044-2023 | |
| (406) 628-8251 | |
| Not Available |
| Full Name | Laurel Health & Rehabilitation Center |
|---|---|
| Type | Facility |
| Speciality | Skilled Nursing Facility |
| Location | 820 3rd Ave, Laurel, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619681079 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Laurel Health & Rehabilitation Center 1777 Avenue Of The States Ste 102, Lakewood, NJ 08701-4779 Ph: (732) 366-8300 | Laurel Health & Rehabilitation Center 820 3rd Ave, Laurel, MT 59044-2023 Ph: (406) 628-8251 |
News Archive
A study based on the tobacco industry's own documents shows the extent of the tobacco industry's efforts to influence the print media on the health effects of secondhand smoke.
A team of researchers from the University of Utah and the University of Massachusetts has identified the first gene associated with frequent herpes-related cold sores.
The global financial crisis should not be allowed to prevent further investments in health and human well-being, said Thoraya Ahmed Obaid, Executive Director of UNFPA, the United Nations Population Fund. The lack of such social investment, she warned, will be most acutely felt in the poorest countries, and will most severely impact those who are socially and economically the most underprivileged—particularly poor women and girls.
Chronic biochemical imbalance is often a primary factor in the development of many complex diseases but a possible metabolic basis for autism has not been well explored. Now Arkansas Children's Hospital Research Institute researchers report for the first time that children with autism have a severely abnormal metabolic profile indicating increased vulnerability to oxidative stress.
A first-in-human study with a new class of antisense oligonucleotide therapeutics showed the ability to target the RNA-silencing drug to the liver, resulting in improved potency and safety at therapeutic doses. The design and results of this trial, conducted in healthy human volunteers are reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
› Verified 2 days ago